Summary
Eli Lilly and Company (LLY) held its 2026 Annual Meeting of Shareholders on May 4, 2026, with a strong turnout of approximately 90% of outstanding shares participating in the vote. Key outcomes include the re-election of four directors, Carolyn Bertozzi, William Kaelin, Jr., Jon Moeller, and David Ricks, to three-year terms. Additionally, shareholders provided advisory approval for the compensation of named executive officers and ratified the appointment of Ernst & Young LLP as the independent auditor for 2026, both with significant support. However, two significant proposals to amend the Company's Articles of Incorporation, one to eliminate the classified board structure and another to remove supermajority voting provisions, failed to gain the required 80% approval from outstanding shares. Furthermore, shareholder proposals requesting an independent board chair and an annual lobbying report were also not approved. These voting results indicate continued shareholder confidence in the current board and executive compensation practices, while also highlighting resistance to certain governance structure changes at this time.
Key Highlights
- 1Four directors (Carolyn Bertozzi, William Kaelin, Jr., Jon Moeller, David Ricks) were re-elected to serve three-year terms ending in 2029.
- 2Shareholders provided advisory approval for the compensation of named executive officers with substantial support.
- 3Ernst & Young LLP was ratified as the independent auditor for 2026.
- 4A proposal to eliminate the classified board structure did not receive the required 80% approval from outstanding shares.
- 5A proposal to eliminate supermajority voting provisions also failed to meet the required 80% approval threshold.
- 6Shareholder proposals for an independent board chair and an annual lobbying report were not approved.